Abivax Shares Drop 5% in Session Despite a Twentyfold Increase in Price Over the Year
The stock of French biotech company Abivax significantly dropped this Monday, April 13, falling to 102.40 euros after closing at 107.90 euros on Friday. This decline of 5.1% occurs in a weakened Paris market environment, with the CAC 40 losing more than 1% during the session. The company, whose stock price has increased more than twentyfold in a year, is experiencing a sharp correction despite a generally favorable recent dynamic.
Abivax Stock Experiences Greater Decline Than Overall Paris Market
Abivax stock has seen a notably greater decline than the overall Paris market this Monday. The CAC 40 is down 1.01% during the session, while the SBF 120 shows similar declines. The pharmaceutical and biotech sector is not spared: Sanofi is down 1.46% and UCB loses 0.87%. Abivax's more pronounced drop is partly explained by a beta of 2.68, indicating a particularly high sensitivity to market movements. The stock's monthly volatility, measured at 56.24, confirms the extent of fluctuations it regularly undergoes. This tense context is fueled by the announcement of an American naval blockade against Iran, initiated this April 13 following the failure of the Islamabad negotiations. Oil has surged above $100 a barrel, reviving fears of major disruptions on global markets. Although Abivax is not directly exposed to raw materials, the generalized risk aversion weighs mechanically on high-volatility stocks like biotechs.
Technical Analysis of Abivax Stock
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
Technically, Abivax's stock price remains above its 20-day and 50-day moving averages, located at 101.15 euros and 101.12 euros respectively, which now serve as a first point of support. The 200-day moving average, at 81.81 euros, remains far off, reflecting the long-term bullish trend supported by an annual performance of nearly 2000%. The RSI, at 60, indicates that the stock is neither in an overbought nor oversold zone, allowing room for movement in both directions. The price is currently positioned midway between the Bollinger Bands, with the upper bound at 113.69 euros and the lower bound at 88.61 euros. This central positioning reflects the absence of extreme signals despite the day's decline. The nearest resistance threshold is at 109.60 euros, while the identified support is at 88.80 euros, close to the lower Bollinger Band. The next financial appointment is scheduled for June 1, 2026, with the publication of the first quarter results.
SectorSanté · Biotechnologies · Vaccins et laboratoires de recherche›Biotechnologie
Context
Period
Period: 3T 2025
Guidance from the release
Trésorerie et équivalents de trésorerie de 589,7 millions d'euros au 30/09/2025 ; perte nette de 254,1 millions d'euros sur les neuf mois ; produit net d'ADS d'environ 700,3 millions de dollars (?597,2 M€) en juillet 2025 ; position financière nette de 543,3 millions d'euros ; autonomie financière attendue jusqu'au T4 2027. Hausse significative des dépenses R&D et des charges G&A.
Risks mentioned
Risques inhérents à la recherche et au développement clinique
Risque lié aux décisions des autorités réglementaires (FDA, EMA)
Risque de disponibilité insuffisante de fonds pour couvrir les dépenses d'exploitation futures
Obstacles potentiels au développement clinique et pharmaceutique (données précliniques, CMC, toxicologie, etc.)
Opportunities identified
Avancement des essais de phase 3 d'Obefazimod en rectocolite hémorragique
Présentations 'late-breaking' et résultats favorables communiqués lors de congrès scientifiques
Produit net élevé de l'offre d'ADS prolongeant l'autonomie financière jusqu'au T4 2027
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
